%0 Journal Article
%T SOHO State of the Art Updates and Next Questions | Hyper-CVAD in 2022: Lessons Learned and New Approaches.
%A Rausch CR
%A Kantarjian HM
%A Jabbour EJ
%J Clin Lymphoma Myeloma Leuk
%V 23
%N 4
%D 04 2023
%M 36872149
%F 2.822
%R 10.1016/j.clml.2023.01.013
%X Combination chemotherapy is the mainstay of treatment for acute lymphoblastic leukemia (ALL). The Hyper-CVAD regimen was developed in 1992 at MD Anderson Cancer Center and has since become a standard of care option for adult patients with ALL. Since its conception, a number of modifications have been implemented to customize the regimen for different patient populations and safely incorporate novel therapies without compromising tolerability. We aim to review the evolution of the Hyper-CVAD regimen over the past 3 decades, focusing on clinical pearls, as well as future directions.